容积旋转调强放疗与FET-PET扫描对胶质母细胞瘤患者治疗结局的影响
分析2005-2014年新诊断胶质母细胞瘤患者,接受60 Gy和替莫唑胺治疗,基于MRI或FET-PET/MR定义靶区,采用适形放疗或海马保护图像引导容积旋转调强放疗。结果示无进展生存期(7个月)和总生存期(15个月)未受放疗技术或FET-PET影响;平均脑剂量较大与较差的无进展生存期和总生存期相关。
要点
- 无进展生存期(7个月)和总生存期(15个月)未受适形放疗、图像引导容积旋转调强放疗或FET-PET技术影响。
- 图像引导容积旋转调强放疗的平均脑剂量低于适形放疗(p < 0.001)。
- 平均脑剂量较大与较差的无进展生存期和总生存期相关(p < 0.001)。
核心结论
- 海马保护图像引导容积旋转调强放疗技术的引入似乎是安全的,可能减少了毒性和认知障碍。
- 较大的平均脑剂量与较差的无进展生存期和总生存期强烈相关。
研究设计与样本
- 分析2005-2014年新诊断胶质母细胞瘤患者,接受60 Gy和替莫唑胺治疗。
- 基于MRI(n = 521)或FET-PET/MR(n = 190)定义GTV和CTV。
- 采用适形放疗(CRT,n = 159)或海马保护图像引导容积旋转调强放疗(IG-VMAT,n = 362)。
- 无进展生存期采用McDonald标准评估,探索临床数据、剂量学数据、治疗技术与无进展生存期和总生存期的关联。
主要发现
- 无进展生存期(7个月)和总生存期(15个月)未受CRT、IG-VMAT和FET-PET技术影响。
- 平均脑剂量与肿瘤体积相关,IG-VMAT组低于CRT组(p < 0.001)。
- 较大的平均脑剂量与较差的无进展生存期相关(单因素/多因素Cox模型,p < 0.001)和总生存期相关(单因素,p < 0.001)。
- 多因素Cox模型显示较大的平均脑干剂量(p < 0.001)、BTV(p = 0.045)、基线使用类固醇(p = 0.003)、年龄(p = 0.019)和MGMT状态(p = 0.022)与较低的总生存期相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We sought to assess the influence of the clinical introduction of new radiotherapy technologies on glioblastoma patients' outcomes. METHODS: Newly diagnosed glioblastoma patients treated with 60 Gy and temozolomide (2005-2014) were analyzed. The patients' GTV and CTV were defined based on MR (n = 521) or FET-PET/MR (n = 190), and were treated using conformal radiotherapy (CRT, n = 159) or image-guided volumetric modulated arc therapy with hippocampal sparing (IG-VMAT, n = 362). Progression-free survival (PFS) was assessed using the McDonald criteria. Associations between clinical data, dosimetry data, treatment technology, for PFS and overall survival (OS) were explored. RESULTS: The PFS (7 months) and OS (15 months) were unaffected by CRT, IG-VMAT and FET-PET technology. Mean brain dose was correlated with tumor volume, and was lower for IG-VMAT vs. CRT (p < 0.001). Larger mean brain dose was associated with inferior PFS (univariate/multivariate Cox models, p < 0.001) and OS (univariate, p < 0.001). Multivariate Cox models revealed association of larger mean brainstem dose (p < 0.001), BTV (p = 0.045), steroid use at baseline (p = 0.003), age (p = 0.019) and MGMT status (p = 0.022) with lower OS. CONCLUSIONS: Introduction of hippocampal-sparing IG-VMAT technology appeared to be safe, and may have reduced toxicity and cognitive impairment. Larger mean brain dose was strongly associated with inferior PFS and OS.
引用
- Munck Af Rosenschold P, Law I, Engelholm S, et al. Influence of volumetric modulated arc therapy and FET-PET scanning on treatment outcomes for glioblastoma patients. Radiother Oncol. 2018. PMID: 30446316. doi:10.1016/j.radonc.2018.10.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。